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studies. Results: We estimated the indirect cost of cancer due to disability in EU 
at the amount of 4223.2 million EUR. However partial disability account for approx. 
20-25% of this sum and reduces potential savings to the amount of 844.6–1055.8 
million EUR. Further correction, taking into account the efficacy of rehabilitation 
programs (up to 85%), reduces this savings to 717.9–897.4 million EUR. Considering 
the loss of productivity due to sickness absence and presenteeism measured in 
cancer survivors’ population (19.1% and 37.3% respectively) potential savings for EU 
economy due to return to work of cancer survivors with a disability are calculated 
at the amount of 364.2-455.2 million EUR. ConClusions: Indirect cost of cancer 
related disability can be reduced, but probably only to a small extent.
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objeCtives: European guidelines recommend colorectal cancer screening of 
average-risk population. Besides cancer, adenomas deserving surveillance through 
colonoscopy, are found. Our objective was to estimate the resources needed to 
undergo the recommended surveillance of adenomas found under a population-
based colorectal cancer screening program. Methods: A previous discrete-event 
simulation model representing a colorectal cancer screening program for a target 
population of women and men aged 50-69 was used. The underlying conceptual 
model was based on the European Guidelines for both the screening process and 
follow-up after adenoma removal. Resources needed according to findings of the 
colonoscopy at screening were the following: genetic tests for polyposis; high-
complexity colonoscopies for high-risk adenomas and polyposis, non-complex 
colonoscopies for intermediate-risk adenomas; visits with gastroenterologists for 
high-risk adenomas and polyposis and with general practitioners for intermediate-
risk adenomas. Parameters were estimated from the Colorectal Cancer Screening 
Program of Barcelona and follow-up colonoscopy results from the literature. A 
20-year horizon starting in 2015 was simulated. The model included population’s 
ageing. Results were rescaled to the population of the whole territory (1.7 million 
target population). Results: The predicted number of colonoscopies at screen-
ing was 19,275, 18,829 and 20,988 for years 2015, 2024 and 2034, respectively. The 
predicted numbers of non-complex and high-complexity colonoscopies were 9,887 
and 7,760 in 2024 and 14,362 and 9,099 in 2034, respectively. The expected num-
ber of gastroenterologist and general practitioner visits were 9,137 and 15,154 in 
2024 and 10,494 and 19,989 in 2034, respectively. The number of genetic tests was 
545 and 659 for years 2024 and 2034, respectively. ConClusions: Implementing 
a population-based colorectal cancer screening program represents an increased 
demand of resources for surveillance of intermediate and high-risk adenomas found 
under the program. Results of the simulation model will allow distributing the 
resources geographically and predicting future need when the screening program 
is extended to all the territory.
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objeCtives: This study assesses frequency of CINV events and resource utiliza-
tion in patients treated with AC for solid cancers Methods: The study evaluated 
a randomly selected cohort of patients from Inovalon’s MORE2Research Edition 
claims database that includes longitudinal data from US health plans. Patients 
who received AC regimens on first day of each cycle in first line of therapy during 
last six months of 2013 were included. Total CINV events and CINV related and 
total hospital/ER visits were captured for cycles of interest in first line and were 
analyzed using chi-square to determine statistical differences between patients 
on NK-1 regimens and non-NK-1 regimens. Results: The study cohort consisted 
of 353 patients, 97% female, 60% with Commercial insurance, and 95% with breast 
cancer, with mean age of 53.1 and Charlson comorbidity score of 6.0. NK-1 based 
CINV regimens were utilized in 73% of the patients in the first chemotherapy cycle. 
Rescue anti-emetics were used by 53% of patients on NK-1 regimens versus 60% 
of patients on non NK-1 regimens. Frequency of CINV events was 41% for NK-1 
versus 45% for the non NK-1 group. Frequency of CINV related ER visits was 5% 
in the NK-1 group versus 12% in the non NK-1 group, p= 0.03. CINV related hospi-
talizations were 3% in the NK-1 group versus 4% in the non-NK-1 group. Total ER 
visits were lower in the NK-1 group compared to the non NK-1 group, 12% versus 
19%; total hospitalizations were also lower in the NK-1 group compared to the non 
NK-1 group, 8% versus 13%. ConClusions: For patients on highly emetogenic 
AC based chemotherapy regimens, NK-1 treatments result in decreased rates of 
CINV events and resource utilization, with CINV related ER visits statistically lower. 
Further studies are warranted to determine if results are generalizable to other 
cancer regimens and diagnoses.
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gressing were 2 813 and 2 703 USD for Docetaxelum and Gefitinibum, respectively. 
Costs of 1 treatment course (21 days) of Pemetrexed were in 1,9 times higher than 
Gefitinibum. Therapy with Gefitinibum increase of life expectancy on 6 months and 
on 0,226 QALY in comparison with Pemetrexed. Costs of 1 month without progres-
sion for Gefitinib were in average 1,8 times less (2 699 and 5 016 USD for Gefitinib 
and Pemetrexed, respectively). Therapy with Gifinitib allows to decrease the direct 
medical costs on 19%. ConClusions: Therapy with Gifinitib as the second line 
therapy in patients with non-small cell lung cancer is effective from clinical and 
economical point of view.
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objeCtives: Reducing premature mortality is a crucial public health objective. A 
widely used measure of premature mortality is years of potential life lost before 
a given age (e.g. age 80). The aim of this study was to analyze the effect that phar-
maceutical innovation had on premature cancer mortality in Portugal during the 
period 2002-2010. Methods: The analysis was performed by using a difference-
in-differences research design based on longitudinal disease-level data, in order to 
investigate whether the diseases that had a larger increase in the number of new 
available drugs (i.e. more pharmaceutical innovation) had larger declines in years of 
potential life lost before age 80 in Portugal. Herein, we present the results specific for 
cancer disease. This methodology controls for the effects of macroeconomic trends 
and overall changes in the healthcare system. Official databases were used, such as 
the Eurostat for the premature mortality data. Results: Drugs registered during 
the period 1994-2002 reduced the number of years of potential life lost to cancer 
before age 80 in 2010 by 26,645. The estimates indicate that if no drugs had been 
registered during 1994-2002, premature mortality from cancer would have increased 
by about 9%. The 2010 expenditure on cancer drugs registered during 1994-2002 
in Portugal was € 148,670,718. Thus, the estimated cost per life-year before age 80 
gained from previous pharmaceutical innovation was € 5,580 (reduction in hospital 
costs due to the impact of pharmaceutical innovation on cancer morbidity were not 
accounted). ConClusions: These findings indicate that pharmaceutical innova-
tion contributed with a significant reduction in the premature mortality caused by 
cancer in Portugal. Moreover, the estimated cost per life-year is well below even the 
lowest estimates of the value of a life-year saved.
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objeCtives: Cancer is the second leading cause of death in Ireland accounting for 
approximately 30% of all deaths. Of these, almost a third arise in those of working 
age. As well as the public health burden, cancer also imposes economic costs on 
society in general and employers in particular. This study measured the productivity 
costs associated with cancer-related premature mortality from an employer’s per-
spective in Ireland. Methods: Data was abstracted on the average annual number 
of cancer deaths between the ages of 15 and 64 in Ireland during 2005-2009 by 5-year 
age group and sex from the World Health Organization Cancer Mortality Database. 
The friction cost approach was used to value all premature cancer deaths (and those 
for the ten most common cancer sites in males and females), over a defined friction 
period (base-case = 79 days), by gross gender- and age-specific wages, adjusted for 
labour market characteristics. In sensitivity analyses estimates were adjusted for 
‘multiplier effects’ associated with modern work practices and for changing labour 
market conditions. Results: The all-cancer premature mortality cost was € 14.3 mil-
lion in 2009. Costs were more than two-fold higher for males than females. Base-case 
estimates were sensitive to changes in labour markets conditions and decreased by 
42% following adjustment for increased unemployment levels (from 4.6% to 12.7%). 
Productivity costs were higher in settings with modern team-based working prac-
tices rising by almost 30% in the case of females (17% for males). ConClusions: 
Employers are becoming increasingly aware of the adverse economic effects of illness. 
Our results reveal the magnitude of productivity costs associated with cancer-related 
premature mortality from an employer’s perspective in Ireland. These results provide 
a sense of the types and magnitude of costs that are explicitly excluded from eco-
nomic evaluations that fail to encompass a broader social perspective.
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objeCtives: The number of cancer survivors is growing due to progression in diag-
nosis and treatment. Approximately half of cancer survivors are at working age, 
however many of them do not return to work. One of the reasons is a disability of 
cancer survivors. Although cancer related disability is usually more severe compared 
to disability due to other diseases, real-life data showed up to 85% of disabled cancer 
survivors may return to work after comprehensive rehabilitation programs. The aim 
of this study was to estimate potential savings to EU economy due to return to work 
of disabled cancer survivors. Methods: Data on indirect cost of a cancer related 
disability were calculated based on Luengo-Fernandez at al. study and our own esti-
mation of a contribution of disability to indirect cost related to morbidity. Disability 
structure i.e. percentage of a partially disabled cancer survivors, was adopted from 
Polish Social Insurance Institution data (we assumed that population with complete 
disability or inability for independent existence can’t return to work). Presenteeism 
and absenteeism in cancer survivors were adopted from our previously published 
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or lenalidomid regimen and cross-sectionally 45.07%/24.73%/8.51% were treated 
by lenalidomid/bortezomib/conventional chemotherapy regimens, mean time to 
progression was 0.81 year. In the 5th line-34.19%/18.36%/18.36% of patients were 
treated by lenalidomid/bortezomib/conventional chemotherapy regimens, mean-
time to progression was 0.88 years. In the 6th line-60.20% of patients were treated 
by conventional chemotherapy. ConClusions: This cross-sectional survey deter-
mined the prevalence and treatment strategies of MM patients in Slovakia accord-
ing to the treatment lines.
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objeCtives: To estimate health care resource use (HCRU) associated with the 
advanced melanoma management in Portugal and to calculate the resulting direct 
medical and non-medical costs. Methods: An expert panel with 6 clinicians from 
the main Portuguese centers treating patients with advanced melanoma was cre-
ated and assessed to estimate HCRU associated with the disease management. A 
two-stage modified Delphi technique was adopted. During the 1st round experts 
answered to a questionnaire concerning resource consumption associated with 
different phases of disease management. At the 2nd round experts discussed and 
validated the mean results obtained from the questionnaires, during a consensus 
meeting. Phases of disease considered were: treatment initiation, progression 
free, post-progression and terminal care. HCRU during progression free phase 
was estimated for two different subsets of patients, according to their previous 
treatment experience: ipilimumab-naïve patients and ipilimumab previously 
treated patients. Medical appointments, laboratory tests, imaging examinations, 
hospitalizations, radiotherapy/radiosurgery and concomitant medications were 
the resources considered. HCRU resulting from adverse events management was 
not included. Costs for each phase were obtained by multiplying mean estimates 
of HCRU by unit costs according to official sources. Oncology drugs costs were 
not included during the treatment phase. Results: Elicited costs per disease 
management phase were the following: 893.4 € for treatment initiation, 1280.4€ /3 
weeks and 1487.5€ /3 weeks for treatment phase, respectively for ipilimumab-naïve 
and ipilimumab previously treated patients. For the BSC phase the cost estimated 
was 1668.7 € /month and the total terminal care cost was 5920.8€ . ConClusions: 
Inpatient costs assumed major role during all phases (except treatment initiation). 
Patient monitoring through medical appointments, laboratory tests and imaging 
examinations had a higher share of resource consumption during treatment phase 
than for patients on BSC. The results from our research are of utmost importance 
to support the cost-effectiveness evaluation of new advanced melanoma treat-
ment strategies.
CANCer – Patient-reported Outcomes & Patient Preference studies
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objeCtives: Adherence to oncologic treatment is a key factor to improve the 
survival of oncologic patients. Several clinical trials reveal non-adherence in these 
patients is common, affecting the health results negatively. The objective is to 
review the published evidence about adherence to oncologic treatment. Methods: 
Systematic review of published articles in PubMed about adherence to oncological 
treatments (January 2005-December 2014) in the European Union. Article selection 
by two independent investigators was based on title and abstract. In addition to 
the incapability to meet other inclusion criteria, the little quality of the results 
was ground for exclusion of a single article. Articles were classified according 
to trial design, type of cancer and adherence measurement method. Results: 
27 publications were analyzed, in which adherence data was described for nine 
different types of cancer and breast cancer was the most studied (51.9% of the 
articles). United Kingdom was the country that carried out the most clinical tri-
als (40.7%). 92.6% of the articles evaluated the adherence of female cohorts and 
48.2% evaluated both men and women cohorts. The most employed methodologies 
to measure adherence were Self-Report, MPR (Medication Possession Ratio) and 
MEMSTM (Electronic Medication Event Monitoring System). 7.4% of the articles 
reported adherence results, 48.2% of adherent to treatment patients and 44.4% of 
both. Adherence ranges fluctuated between 25.9% and 100% while the ranges of 
adherent patients oscillated between 7.84% and 92%. Age was one of the factors 
that affected adherence to oncological treatments (patients under 60 and over 75 
were less adherent to oncological treatments). ConClusions: Disparity in cri-
teria and measurement methods contributes to the great heterogeneity of adher-
ence and adherent patients published data. The poor adherence levels retrieved 
confirm the need of implementing healthcare interventions to foster adherence, 
given its impact on both oncological treatments effectiveness and healthcare 
systems sustainability.
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objeCtives: Electronic data capture of patient-reported outcomes (ePRO) offers effi-
ciency, greater accuracy and improved compliance vs paper. However, mode equiva-
lence and device usability needs to be demonstrated, per ISPOR ePRO Research 
1Kantar Health, Montrouge, France, 2Hôpital Morvan - CHU de Brest, BREST, France, 3Hôpital 
Albert Michallon - CHU de Grenoble, LA TRONCHE, France, 4MSD France, COURBEVOIE, France, 
5MSD France, Courbevoie, France, 6Hôpital Dupuytren - CHU de Limoges, LIMOGES, France, 
7Amaris, Paris, France
objeCtives: The objective of the AMEL study was to describe healthcare resource 
utilization (HCRU) among advanced melanoma patients according to the treat-
ment they received in order to assess the mean cost per line of therapy according 
to the treatment received. Methods: The study was a retrospective observa-
tional study using medical records. 33 physicians participated in the research. 
Each physician documented all of their patients diagnosed with advanced cuta-
neous melanoma between January 1st 2012 and October 31st 2012. Resource use 
related to hospitalizations, outpatient visits, radiotherapy and imaging tests 
were collected throughout the patient pathway, from diagnosis to end of the data 
extraction or death, whichever occurred first. The costing was based on ENCC 
reference costs. Results: After exclusion of the patients whose treatment was 
part of a clinical trial, HCRU could be assessed for 220 patients who received 1st 
line treatment, 144 2nd line and 67 3rd line. Hospital consumption increased 
together with the line of therapy. The proportion of patients experiencing at least 
one hospitalization was 46.4%, 50.7% and 62.7% in 1st, 2nd and 3rd line and the 
mean length of stay was 14,39, 15.6 and 17.3 days respectively. In 1st line, the main 
cause of hospitalization was treatment administration (41.2% of patients) while 
it was palliative care in 2nd and 3rd line (52.1% and 54.8%). Hospitalization due to 
treatment toxicities occurred in 18.6% of first line patients, with a mean length of 
stay of 20.21 days and was less frequent in 2nd and 3rd line (6.8 and 9.5%). After 
valorization, the mean hospital cost per patient was 1,526€ in 1st line, 2,098€ in 
2nd and 2,250€ in 3rdline. ConClusions: Health care consumption, including 
hospitalization, increased together with evolution of the disease, with the most 
costly period being the “terminal state”.
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objeCtives: Subcutaneous versions of different oncology therapies are available 
since few years for which the patient-relevant and hospital benefits have not been 
assessed in real life. Methods: In order to analyze the impact of subcutaneous 
administrations for rituximab or trastuzumab in comparison to the respective intra-
venous mode a primary research in Italy was executed. The study’s primary objec-
tives were to analyze the resource and cost implications from different perspectives 
(patient, medical staff) in real world. The route of administration was discussed 
and aligned with the participating centers in order to capture all relevant therapy 
parts. After the successful execution of a pilot study 33 centers in 6 regions in 
Italy were recruited to participate. Results: Significant time savings are achieved 
with the subcutaneous mode through significantly lower patient preparation time 
including less time preparing the actual dosing for each individual patient. The total 
time difference is 3.3 hours with rituximab in hematology (NHL) which adds up to 
23.55 hours for a full course of treatment per patient (overall preparation time: 40.1 
hours intravenous [95%CI: +0.47] vs 16.6 hours subcutaneous [95%CI: +0.2]). In early 
breast cancer (trastuzumab) the time saving is 3.3 hours for the first cycle and the 
total time saving for patient preparation is 17.2 hours (overall preparation time: 
38.8 hours intravenous [95%CI: +9.42] vs 21.6 hours subcutaneous [95%CI: +9.9]). 
Furthermore in both settings the time of medical stuff was reduced and could hence 
be used elsewhere. Finally in case wastage was experienced with intravenous thera-
pies there were significant reductions in wastage through the subcutaneous admin-
istration (93% to 100%) with cost savings of 6’057 € with rituximab subcutaneous 
and 28’399 € with trastuzumab subcutaneous administration, respectively for the 
full treatment course. ConClusions: There are significant resource and cost sav-
ings due to subcutaneous administration with rituximab and trastuzumab in Italy.
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objeCtives: The latest official national data on epidemiology of multiply mye-
loma (MM) are available for year 2008. Estimated incidence for 2015 represents in 
both sexes 311 cases (age-standardized (ASR-W) incidence 3.1/100,000), mortality 
176 cases (ASR-W 1.6/100,000), prevalence 1,715 patients. The objective of this 
cross-sectional survey was to define prevalence and treatment strategies used in 
MM patients according to the treatment lines and provide a basis for the budget 
impact analysis (BIA). Methods: Data on treatment of 656 MM patients from 7 
MM-centers in 2013 from whole Slovakia were collected and analyzed. Continuous 
variables were calculated using standard descriptive statistics methods Results: 
86.9% of patients were cross-sectionally on active treatment. In the 1st clinical 
stage (according to Durie and Salmon classification) were 13.03% of patients, in 
the 2nd clinical stage-32.07%, in the 3rd clinical stage-54.09%. The treatment 
strategies were as followed: In the 1st line-36.34% of patients underwent BMT, 
outside them 80.53% were on bortezomib regimen, mean-time to progression rep-
resented 2.31 years. In the 2nd line-22.83% (out of 36.34%) of patients underwent 
re-transplant, outside them 68.50% were on lenalidomid regimen, mean-time to 
progression was 1.65 years. In the 3rd line-42.84%/21.71%/12.97% of patients were 
on bortezomib/lenalidomid/bendamustine regimens, mean-time to progression 
represented 1.29 year. 40.88% of all registered patients were in 2013 treated by 
the 4th line, 90.45% out of them had previously been treated by bortezomib and/
